Anticancer agents from unique natural products sources

Pharmaceutical Biology

Volumn 41, Issue SUPPL., 2003, Pages 15-38

  Ireland, Chris M ^a   Aalbersberg, William ⁱ   Andersen, Raymond J ^e   Ayral Kaloustian, Semiramis ^c   Berlinck, Roberto G S ^h   Bernan, Valerie ^c   Carter, Guy ^c   Churchill, Alice C L ^j   Clardy, Jon ^f   Concepcion, Gisela P ^b   De Silva, E Dilip ^g   Discafani, Carolyn ^c   Fojo, Tito ^d   Frost, Philip ^c   Gibson, Donna ^k   Greenberger, Lee M ^c   Greenstein, Michael ^c   Harper, Mary Kay ^a   Mallon, Robert ^c   Loganzo, Frank ^c   Nunes, Maria ^c   Poruchynsky, Marianne S ^d   Zask, Arie ^c   more..

^a UNIVERSITY OF UTAH   (United States)

^b University of the Philippines Diliman   (Philippines)

^c PFIZER INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF COLOMBO   (Sri Lanka)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ UNIVERSITY OF THE SOUTH PACIFIC   (Fiji)

^j United States Department of Agriculture Agricultural Research Service and Boyce Thompson Institute for Plant Research   (United States)

^k ROBERT W HOLLEY CENTER FOR AGRICULTURE AND HEALTH   (United States)

more..

Author keywords

Antitumor agents; Austocystins; Fungi; Hemiasterlins; Marine microorganisms; Natural Products; NCDDG; Sponges

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADENOSINE TRIPHOSPHATE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AUSTOCYSTIN D; CALICHEAMICIN; CELL DNA; CRIAMIDE A; CYCLIN B; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; HEMIASTERLIN; HEMIASTERLIN A; HEMIASTERLIN B; JASPAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; NAMENAMICIN; NATURAL PRODUCT; PACLITAXEL; POLYKETIDE SYNTHASE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RAF PROTEIN; STAUROSPORINE; TALTOBULIN; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CONFERENCE PAPER; COOPERATION; DRUG INDUSTRY; DRUG ISOLATION; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; FUNGUS; HUMAN; IC 50; MARINE ENVIRONMENT; NONHUMAN; ONCOGENE; STRUCTURE ACTIVITY RELATION; SUPPRESSOR GENE;

FUNGI;

EID: 9444295342     PISSN: 13880209     EISSN: None     Source Type: Journal    
DOI: 10.1080/1388020039051742     Document Type: Conference Paper

References (83)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel R (1995): PD-098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489-27494.
2. Alessi DR, Cohen P, Ashworth A, Cowley S, Leevers SJ, Marshall CJ (1995): Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol 255: 279-290.
3. Altmann KH (2003): Epothilone B and its analogs - a new family of anticancer agents. Mini Rev Med Chem 3: 149-158.
4. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990): Basic local alignment search tool. J Mol Bio 215: 403-410.
5. An K-D, Nishida H, Miura Y, Yokota A (2003): Molecular evolution of adenylating domain of aminoadipate reductase. BMC Evol Biol 3: 9-15 (http://www.biomedcentral.com/ 1471-2148/3/9).
6. Anderson HJ, Coleman JE, Andersen RJ, Roberge M (1997): Cytotoxic peptides hemiasterlin, hemiasterlin A, and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol 39: 223-226.
7. Andersen RJ, Coleman JE, Piers E, Wallace DJ (1997): Total synthesis of (-)-hemiasterlin, a structurally novel tripeptide that exhibits potent cytotoxic activity. Tetrahedron Lett 38: 317-320.
8. Andersen RJ, Piers E, Nieman J, Coleman J, Roberge M (1999): WO Patent 99/3250.
9. Angeles TS, Steffler C, Bartlett BA, Hudkins RL, Stephens RM, Kaplan DR, Dionne CA (1996): Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity. Anal Biochem 236: 49-55.
10. Bai R, Durso NA, Sackett DL, Hamel E (1999): Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 38: 14302-14310.
11. Barbacid M (1987): RAS Genes. Ann Rev Biochem 56: 779-822.
12. Boyd, MR (1989): Status of the NCI preclinical drug discovery screen. In: Principles and Practices of Oncology 3, pp. 1-10, J.B. Lippincott Publish.
13. Coleman JE, de Silva ED, Kong F, Andersen RJ, Alien TM (1995): Cytotoxic peptides from the marine sponge Cymbastela sp. Tetrahedron 51: 10653-10662.
14. Coleman JE, Patrick BO, Andersen RJ, Rettig SJ (1996): Hemiasterlin methyl ester. Acta Cryst C52: 1525-1527.
15. Crews P, Farias JJ, Emrich R, Keifer PA (1994): Milnamide A, an unusual cytotoxic tripeptide from the marine sponge Auletta cf. constricta J Org Chem 59: 2932-2934.
16. 2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem 276: 17914-17919.
17. de Suva ED, Andersen RJ, Allen TM (1990): Geodiamolide C to Geodiamolide F, new cytotoxic cyclodepsipeptides from the marine sponge Pseudaxinyssa sp. Tetrahedron Lett 31: 489-492.
18. Discafani CM, Carroll ML, Floyd Jr MBF, Hollander IJ, Husain Z, Johnson BD, Kitchen D, May MK, Malo MS, Minnick Jr AA, Nilakantan R, Shen R, Wang Y-F, Wissner A, Greenberger LM (1999): Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[3-bromophenyl) amino]-6-quinaxolinyl]-2-butynamide (CL-387,785). Biochem Pharmacol 57: 917-925.
19. Downing, KH (2000): Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 16: 89-111.
20. Dumontet C (2000): Mechanism of action and resistance to tubulin-binding agents. Exp Opin Invest Drugs 9: 779-788.
21. Foulkes WD, Flanders TY, Pollock PM, Hayward NK, (1997): The CDKN2A (p16) gene and human cancer. Mol Med 3: 5-20.
22. Gamble WR, Durso NA, Fuller RW, Westergaard CK, Johnson TR, Sackett DL, Hamel E, Cardellina JH, Boyd MR (1999): Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina sponges. Bioorg Med Chem 7: 1611-1615.
23. Gibbons JJ, Discafani C, Peterson R, Hernandez R, Skotnicki J, Frost P (1999): The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Proc Am Assoc Cancer Res 40: 301.
24. Gibbs (2000): Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest 105: 9-13.
25. Gottesman MM (2002): Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
26. Gottesman MM, Fojo T, Bates SE (2002): Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
27. Hall M, Peters G (1996): Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68: 67-108.
28. Hamel E (1996): Antimitotic natural products and their interactions with tubulin. Med Res Rev 16: 207-231.
29. Hamel E, Covell DG (2002): Antimitotic peptides and depsipeptides. Curr Med Chem Anti-Canc Agents 2: 19-53.
30. Hanks SK, Hunter T (1995): The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB 9: 576-596.
31. He H, Ding W-D, Bernan VS, Richardson AD, Ireland CM, Greenstein M, Ellestad GA, Carter GT (2001): Lomaiviticins A and B, potent antitumor antibiotics from Micromonospora lomaivitiensis. J Am Chem Soc 123: 5362-5363.
32. Hirama T, Koeffler HP (1995): Role of the cyclin-dependent I kinase inhibitors in the development of cancer. Blood 86: 841-854.
33. Hunter T (1997): Oncoprotein networks. Cell 88: 333-346.
34. Imamura N, Nishijima M, Takadera T, Adachi K, Sakai M, Sano H (1997): New anticancer antibiotics pelagiomicins, produced by a new marine bacterium Pelagiobacter variabilis. J Antibiot 50: 8-12.
35. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skolnick MH (1994): A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
36. 3H] benzophenone analogs of HTI-286. National Medicinal Chemistry Symposium: abstract 49.
37. Kfir R, Johannsen E, Vleggaar R (1986): Mutagenic activity of austocystins-secondary metabolities of Aspergillus ustus. Bull Environ Contam Toxicol 37: 643-650.
38. Kolch W (2000): Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351: 289-305.
39. Kramer RA, Zakher J, Kim G (1988): Role of glutathione redox cycle in acquired and de novo multidrug resistance. Science 241: 694-698.
40. Kramer RA, Weber TK, Morse B (1993): Constitutive expression of multidrug resistance in human colorectal tumors and cell lines. Br J Cancer 67: 959-968.
41. Lackey K, Cory M, Davis R, Frye SV, Harris PA, Hunter RN, Jung DK, McDonald OB, McNutt RW, Peel MR, Rutkowske RD, Veal JM, Wood ER (2000): The discovery of potent cRaf-1 kinase inhibitors. Bioorg Med Chem Lett 10: 223-226.
42. Lavoie JN, L'Allemain G, Brunei A, Muller R, Pouyssegur J (1996): Cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271: 20608-20616.
43. Lee T, Yun S-H, Hodge KT, Humber RA, Krasnoff SB, Turgeon GB, Yoder OC, Gibson DM (2001): Polyketide synthase genes in insect- and nematode-associated fungi. Appl Microbiol Biotechnol 56: 181-187.
44. Leraer EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti M (1997): Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15: 1283-1288.
45. Levitzki A, Gazit A (1995): Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788.
46. Lewis TS, Shapiro PS, Ahn NG (1998): Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139.
47. Loganzo F, Annable T, Xingzhi T, Morilla DB, Hari M, Musto S, Zask A, Kaplan J, Poruchynsky M, Fojo TMGL (2003): Cells resistant to HTI-286 do not over-express P-glycoprotein but have low drug accumulation and a point mutation in α-tubulin. Proc Amer Assoc Cancer Res 44: 1307 (2nd ed.).
48. Loganzo F, Discafani C, Annable T, Beyer C, Musto S, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM (2003): HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 63: 1838-1845.
49. Mallon R, Feldberg LR, Kim SC, Collins K, Wojciechowicz D, Hollander I, Kovacs ED, Kohler C (2001): An enzyme-linked immunosorbent assay for the Raf/MEK-1/MAPK signaling cascade. Anal Biochem 294: 48-54.
50. Martin JF (1998): New aspects of genes and enzymes for β-lactam antibiotic biosynthesis Appl. Microbiol Biotechnol 50: 1-15.
51. McDonald LA, Capson TL, Krishnamurthy G, Ding W, Ellestad GA, Bernan VS, Maiese WM, Lassota P, Discafani C, Kramer RA, Ireland CM (1996): Namenamicin, a new enediyne antitumor antibiotic from the marine ascidian Polysyncraton lithostrotum. J Amer Chem Soc 118: 10898-10899.
52. McDonald OB, Chen WJ, Ellis B, Huffman C, Overton L, Rink M, Smith A, Marshall CJ, Wood ER (1999): A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. Anal Biochem 268: 318-329.
53. Meijer L, Kim S-H (1997): Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol 283: 113-128.
54. Meijer L, Thunnissen A-MWH, White AW, Garnier M, Nikolic M, Tsai L-H, Walter J, Cleverley KE, Salinas PC, Wu Y-Z, Biernat J, Mandelkow E-M, Kim S-H, Pettit GR (2000): Inhibition of cyclin-dependent kinases, GSK-3 and CK1, by hymenialdisine, a marine sponge constituent. Chem Biol 7: 51-63.
55. Mithani S, Weeratunga G, Taylor NJ, Dmitrienko GI (1994): The kinamycins are diazofluorenes and not cyanocarbazoles. J Amer Chem Soc 116: 2209-2210.
56. Morgan DO (1995): Principles of CDK regulation. Nature 374: 131-134.
57. Monks A, Scudiero D, Skehan P (1991): Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766.
58. Nieman J, Coleman J, Wallace D, Piers E, Lim LY, Roberge M, Andersen RJ (2003): synthesis and antimitotic/cytotoxic activity of hemiasterlin analogs. J Nat Prod 66: 183-199.
59. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994): Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756.
60. Nogales E, Whittaker M, Milligan RA, Downing KH (1999): High-resolution model of the microtubule. Cell 96: 79-88.
61. Nunes M, Kaplan J, Loganzo F, Zask A, Ayral-Kaloustian S, Greenberger L (2002): Two photoaffinity analogs of HTI-286, a synthetic analog of hemiasterlin, interact with alpha-tubulin. Eur J Cancer 38: S119.
62. O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS (1999): c-Raf-1 depletion and tumor responses in patients treated with the c-Raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res 5: 3977-3982.
63. Pang L, Sawada T, Decker SJ, Saltiel AR (1995): Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 23: 13585-13588.
64. Pawson T, Saxton TM (1999): Signaling networks-do all roads lead to the same genes? Cell 97: 675-678.
65. Poruchynsky MS, Kim JH, Nogales E, Loganzo F, Greenberger LM (2003): Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analog, HTI-286, have mutations in α- or β-tubulin and increased microtubule stability. Proc Am Assoc Cancer Res 44: 535 (2nd ed.).
66. Ratain MJ, Undevia S, Janisch L, Roman S, Mayer P, Buckwalter M, Foss D, Hamilton BL, Fischer J, Bukowski RM (2003): Phase I and pharmacological study of HTI-286, a novel antimicrotubule agent: correlation of neutropenia with time above threshold plasma concentration. Proc Am Soc Clin Oncol: abstract 516.
67. Roberge M, Cinel B, Anderson HJ, Lim L, Jiang X, Xu L, Kelly MT, Andersen RJ (2000): Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin, and paclitaxel in natural extracts. Cancer Res 60: 5052-5058.
68. Robinson MJ, Cobb MH (1997): Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186.
69. Rowinsky EK, Tolcher AW (2001): Antimicrotubule Agents. In: Devita Jr VT, Hellman S, Rosenberg SA, eds., Cancer Principles and Practice. 6th ed., Philadelphia, Lippincott Williams and Wilkins, pp. 431-452.
70. Salomon DS, Brandt R, Ciadiello F, Normanno N (1995): Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 19: 183-232.
71. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR (1999): Blockade of the MAP kinase pathway supresses growth of colon tumors in vivo. Nat Med 5: 810-816.
72. Stehelin D, Varmus HE, Bishop JM, Vogt PK (1976): DNA related to the transforming gene of avian sarcoma virus is present in normal avian DNA. Nature 260: 170-173.
73. Steyn PS, Vleggaar R (1974): Austocystins. Six novel dihydrofurol[3′,2′:4,5]furo[3,2-b]xanthenones from Aspergillus ustus. J Chem Soc Perkin I 19: 2250-2256.
74. Steyn PS, Vleggaar R (1975): Dihydroruro[3′,2′:4,5]furo[3,2- b]xanthenones: the structures of austocystins G, H, and I. J South African Chemical Institute 28: 375-377.
75. Strawn, LM, Shawver LK (1998): Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp Opin Invest Drugs 7: 553-573.
76. Talpir R, Benayahu Y, Kashman Y, Pannell L, Schleyer M (1994): Hemiasterlin and geodiamolide-TA - 2 new cytotoxic peptides from the marine sponge Hemiasterella minor (Kirkpatrick). Tetrahedron Lett 35: 4453-4456.
77. Tasdemir D, Mallon R, Greenstein M, Feldberg LR, Kim SC, Collins K, Wojciechowicz W, Mangalindan GC, Concepción GP, Harper MK, Ireland CM (2002): Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1) J Med Chem 45: 529-532.
78. U.N. Convention on Biological Diversity, June 2, 1992, U.N. Doc. DPI/130/7.
79. Weber G, Schorgendorfer K, Schneider-Scherzer E, Leitner E (1994): The peptide synthetase catalyzing eyclosporine production in Tolypocladium niveum is encoded by a giant 45.8-kilobase open reading frame. Curr Genet 26: 120-125.
80. Weinber RA (1991): Molecular Biology of Carcinogenesis. In: Broder S, ed., Molecular Foundations of Oncology. Williams & Wilkins, pp. 27-39.
81. Woodburn JR (1999): The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250.
82. Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, Sausville EA (1999): Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res 59: 2566-2569.
83. Zask A, Birnberg G, Cheung K, Cole D, Kaplan J, Niu C, Norton E, Sandanayaka V, Suayan R, Tang Z, Yamashita A, Loganzo F, Beyer C, Discafani C, Greenberger LM, Ayral-Kaloustian S (2002): Synthesis and biological activity of analogs of the antimicrotubule agent HTI-286. Proc Amer Assoc Cancer Res 43: 737.